Pascal Soriot

Sir Pascal Claude Roland Soriot is a French-born Australian businessman and chief executive officer of the British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca, Inc.(AZN)

Career :

Roussel Uclaf - 

In April 1986, he joined Roussel Uclaf (formerly France's second largest pharmaceutical company, until bought by Hoechst AG in 1997) as a salesman in Australia. In 1996, he became General Manager of Hoechst Marion Roussel in Australia, moving to Tokyo in April 1997.

Aventis -

In 2000 he moved to Aventis in America, becoming chief operating officer of Aventis USA in 2002, which became Sanofi Aventis USA in 2004

Roche - 

He joined Roche in 2006. From April 2009 to 2010, he was chief executive of the Roche subsidiary Genentech. He rejoined Roche Pharma AG in 2010 as chief operating officer.

AstraZeneca - 

In August 2012 he was named as the new chief executive of AstraZeneca, the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012.

In July 2017, it was reported that Soriot would become the next CEO of Israel-based Teva Pharmaceutical Industries, succeeding Erez Vigodman, though this was soon denied.

In September 2018, he made headlines commenting on his pay of £9.4m in salary and bonuses. 'The truth is I’m the lowest-paid CEO in the whole industry', he said. 'It is annoying to some extent. But at the end of the day it is what it is.'